Two years ago, researchers at the University of Pennsylvania showed for the first time that it was safe and feasible to infuse cancer patients with millions of their own immune cells that had been edited with the DNA-snipping technology known as CRISPR. To make them more efficient tumor torpedoes, scientists added a single synthetic receptor that locks on to a molecule produced by many types of cancer.
Now, a team led by the Bay Area-based biotech PACT Pharma and researchers at the University of California, Los Angeles, have infused individualized cocktails of CRISPR-edited immune cells into 16 cancer patients with minimal and manageable side effects. Each one received a custom mixture of T cells carrying new receptors tuned to their specific tumors.
And unlike earlier efforts, which relied on viral vectors to endow T cells with cancer-targeting capabilities, in this trial researchers engineered this arsenal of cancer-seeking T cells using only CRISPR and a zap of electricity.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect